Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Biohaven Pharmaceutical Holding Co (DE:2VN)
FRANKFURT:2VN
RESEARCH TOOLSreports
Biohaven Pharmaceutical Holding Co (2VN) Stock Forecast & Price Target
0 Followers
See the Price Targets and Ratings of:
2VN Analyst Ratings
Hold
0 Buy
2 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
2VN Stock 12 Month Forecast
Average Price Target
―| Highest Price Target€136.30 | Average Price Target€136.30 | Lowest Price Target€136.30 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Piper Sandler
―
Hold
―
Downgraded
08/19/22
Analysts Conflicted on These Healthcare Names: Cytokinetics (NASDAQ: CYTK), Aeglea Biotherapeutics (NASDAQ: AGLE) and Biohaven Pharmaceutical Holding Co (NYSE: BHVN)
Wedbush
€136.30
Hold
―
Downgraded
08/08/22
Biohaven Pharmaceutical downgraded to Neutral from Outperform at WedbushBiohaven Pharmaceutical downgraded to Neutral from Outperform at Wedbush
Morgan Stanley
€136.30
Hold
―
Reiterated
05/11/22
Analysts Offer Insights on Healthcare Companies: Haemonetics (NYSE: HAE), Crispr Therapeutics AG (NASDAQ: CRSP) and Biohaven Pharmaceutical Holding Co (NYSE: BHVN)
H.C. Wainwright
€136.30
Hold
―
Downgraded
05/11/22
Analysts Have Conflicting Sentiments on These Healthcare Companies: Anavex Life Sciences (NASDAQ: AVXL) and Biohaven Pharmaceutical Holding Co (NYSE: BHVN)
SVB Securities
€137.68
Hold
―
Downgraded
05/10/22
SVB Leerink downgrades Biohaven Pharmaceutical Holding (BHVN) to Market PerformSVB Leerink analyst Marc Goodman downgraded Biohaven Pharmaceutical Holding (NYSE: BHVN) from Outperform to Market Perform with a price target of $150.00.
William Blair
―
Buy
―
Reiterated
04/04/22
William Blair reiterates Outperform Rating on Biohaven Pharmaceutical (BHVN), Sees Nurtec ODT as Leader in Migraine TherapiesWilliam Blair analyst Tim Lugo reiterated an Outperform rating on Biohaven Pharmaceutical Holding (NYSE: BHVN)
Cantor Fitzgerald
€162.46
Buy
―
Reiterated
01/04/22
Biohaven Pharmaceutical Holding (BHVN) Likely to Pre-Release NURTEC-OTD Sales - Cantor FitzgeraldThe analyst stated "Over the first three quarters of 2021, Biohaven blew past our and FactSet consensus estimates in notable fashion (see notes for 1Q, 2Q, and 3Q). With the recent approvals in the prevention indication by the oral-CGRP class and NURTEC-ODTs continued label differentiation, it is our view that the company will achieve its New Years resolutions by exceeding revenue projections, despite the bar being raised. Our 4Q21 sales projection for Biohaven is $159.9M (+355% YoY, +18% QoQ) compared to consensus (FactSet) of $155.2M (+342% YoY, +14% QoQ). The company is coming off a 3Q21 revenue beat, which we believe is the result of new patient adds, for both acute andprevention, and payor reimbursement further kicking in, which was more than enough to overcome seasonal summer headwinds and fuel 46% QoQ revenue growth."
Canaccord Genuity
€146.86
Buy
―
Reiterated
01/03/22
Biohaven Pharmaceutical price target raised to $160 from $150 at CanaccordBiohaven Pharmaceutical price target raised to $160 from $150 at Canaccord
UBS
€101.88
Hold
―
Reiterated
11/11/21
Biohaven Pharmaceutical Holding (BHVN) PT Raised to $111 at UBSUBS analyst Esther Rajavelu raised the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $111.00 (from $109.00) while maintaining a Neutral rating.
2VN Analyst Recommendation Trends
Currently, no data available
Please return soon. This page is being updated.
Each month's total comprises the sum of three months' worth of ratings.
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
2VN Financial Forecast
2VN Stock Forecast FAQ
What is DE:2VN’s average 12-month price target, according to analysts?
Based on analyst ratings, Biohaven Pharmaceutical Holding Co’s 12-month average price target is €136.30.
What is DE:2VN’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for DE:2VN, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Biohaven Pharmaceutical Holding Co a Buy, Sell or Hold?
Biohaven Pharmaceutical Holding Co has a conensus rating of Hold, which is based on 0 buy ratings, 2 hold ratings and 0 sell ratings.
What is Biohaven Pharmaceutical Holding Co’s share price target?
The average share price target for Biohaven Pharmaceutical Holding Co is €136.30. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €136.30 ,and the lowest forecast is €136.30. The average share price target represents N/A Increase from the current price of N/A.
The highest analyst share price target is €136.30 ,and the lowest forecast is €136.30. The average share price target represents N/A Increase from the current price of N/A.
What do analysts say about Biohaven Pharmaceutical Holding Co?
Biohaven Pharmaceutical Holding Co’s analyst rating consensus is a Hold. This is based on the ratings of 2 Wall Streets Analysts.
How can I buy shares of Biohaven Pharmaceutical Holding Co?
To buy shares of DE:2VN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.